Skip to main content
. 2009 Apr 21;100(10):1558–1565. doi: 10.1038/sj.bjc.6605050

Table 1. Earlier research on the QoL in gynaecological cancer patients.

Author Study design Cancer Number QoL instrument Results
Bye et al (2000) Cross-sectional Endometrial and cervical 79 EORTC QLQ-C36 Lower QoL in the areas of diarrhoea and role functioning than in normal population 3–4 years after radiotherapy. Pain and diarrhoea associated with decrease in QoL
Klee et al (2000a) Prospective cohort Cervical and vaginal 118 EORTC QLQ-C30 Overall QoL reduced compared with a control group, even at 24 months after treatment
Klee et al (2000b) Prospective cohort Cervical 118 EORTC QLQ-C30 Acute physical symptoms up to 3 months after treatment. Frequent voiding and diarrhoea may become chronic symptoms
Klee and Machin (2001) Prospective cohort Endometrial 49 EORTC QLQ-C30 Physical symptom scores were highest immediately after treatment. Global QoL lower than healthy controls
Leake et al (2001) Cross-sectional Gynaecological 202 FLI-C Treatment with radiotherapy is associated with deterioration in QoL scores
Greimel et al (2002) Prospective cohort Gynaecological or breast 248 EORTC QLQ-C30 Decrease in global QoL, emotional functioning and role functioning up to 1 year after treatment
Lutgendorf et al (2002) Prospective cohort Gynaecological 98 FACT-G, POMS Decrements in physical, functional and total well-being reported at baseline. Improvements in QoL and mood by 1 year
Frumovitz et al (2005) Cross-sectional Cervical 114 SF-12, BSI-18, A-DAS, CARES, FSFI Patients treated with radiotherapy had a worse sexual functioning than those treated with surgery alone
Wenzel et al (2005) Cross-sectional Cervical 51 SF-36, QOL-CS, IES, GPC, SAQ, ISEL, FACT-Sp, COPE QoL and functioning in cervical cancer survivors comparable with age-matched controls. Cancer-specific distress, spiritual well-being, maladaptive coping and reproductive concerns are predicative of individual QoL
Bradley et al (2006) Cross-sectional Cervical and endometrial 152 SF-36, FACT-G, CES-D, POMS No significant differences in QoL or depressive symptoms between cancer survivors or healthy controls. However, cervical cancer survivors report more negative mood
Vistad et al (2006) Critical review Cervical 2041 Self-report measures QoL in cervical cancer survivors is reduced compared with the general population after radiotherapy
Vistad et al (2007) Cross-sectional Cervical 79 FQ, HADS, SF-36, SAQ, LENT- SOMA Almost one-third of cervical cancer survivors report chronic fatigue (CF). Those with CF had significantly lower QoL and higher levels of depression, anxiety and physical impairment
Distefano et al (2008) Prospective cohort Cervical 93 SF-36, HADS QoL scores comparable between locally advanced cervical cancer patients receiving pre-operative chemotherapy and those with early stage disease. Poor QoL scores associated with anxiety disorders, low educational level and unemployment status
Greimel et al (2008) Cross-sectional Cervical 121 EORTC QLQ-C30, QLQ-CX24, SAQ Patients treated with adjuvant radiotherapy are more likely to have impaired QoL than those treated with surgery or adjuvant chemotherapy

A-DAS=Abbreviated Dyadic Adjustment Scale; BSI-18=Brief Symptom Inventory 18; CARES=Cancer Rehabilitation Evaluation System; CES-D=Center for Epidemiologic Studies Depression scale; COPE=Coping Orientations to Problems Experienced Scale; EORTC=European Organisation for the Research and Treatment of Cancer; FACT-G=Functional Assessment of Cancer Therapy (General); FACT-Sp=Functional Assessment of Cancer Therapy-Spirituality Scale; FLI-C=Functional Living Index; FQ=Fatigue Questionnaire; FSFI=Female Sexual Function Index; GPC=Gynecologic Problems Checklist; HADS=Hospital and Depression Scale; IES=Impact of Event Scales; ISEL=Interpersonal Support Evaluation List; LENT SOMA=Late Effects of Normal Tissue, Subjective Objective Management Analysis; POMS=Profile of Mood States; QoL-CS=Quality of Life – Cancer Survivorship; SAQ=Sexual Activity Questionnaire; SF-12=Short Form 12; SF-36=Short Form 36.